AKT1 and melanoma: Our results suggest that the combination of DSeA and TRAIL could be a novel strategy to overcome PI3K/Akt signaling pathway-mediated resistance in malignant melanoma cells and DSeA may be candidates for further evaluation as a chemosensitizer in clinical trails.